retatrutide study news today 🚨Breaking: Retatrutide's first Phase 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Lilly's next act in diabetes

However, the weight loss effects may be less noticeable if you use sub-therapeutic doses for microdosing, as the body does not receive a strong enough dose to activate the full therapeutic mechanisms

See a complete list of Orlistat side effects here

J Diabetes Res (2015) 2015:114

Later studies showed similar benefits for people without diabetes, but who had obesity or elevated heartdisease risk

Is it appropriate for your bodyweight and phase

In inguinal WAT, direct comparison between Gipr fl/fl vehicle-treated and Gipr fl/fl mGIPR-Ab/P1-treated mice resulted in 1,118 differentially expressed genes (DEGs) with 450 upregulated and 668 downregulated genes